drugset / Trial / NCT03201250
Cabozantinib as a Targeted Strategy to Reverse Carfilzomib Resistance in Refractory Multiple Myeloma
NaSingle-groupOpen-labelTreatment
Summary
In the currently proposed phase I/II study, the investigators aim to treat patients with relapsed and/or relapsed refractory Multiple Myeloma who have progressed on carfilzomib-based therapy with an FDA approved c-MET inhibitor, cabozantinib.
Timeline
- Start
- 2018-02-21
- Primary completion
- 2021-04-12
- Completion
- 2021-04-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cabozantinib | Small molecule | 20 mg | Oral |
| Subject | Cabozantinib | Small molecule | 40 mg | Oral |
| Subject | Cabozantinib | Small molecule | 60 mg | Oral |